Clinical Trial Update: Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of fulvestrant and abemaciclib with a fulvestrant run-in for estrogen receptor-positive, HER2-negative metas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: ER-Positive Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Status: RECRUITING